Form 4: Capricor Therapeutics Director Exercises Stock Options
SEC Filing
Earl M Collier Jr., a director at Capricor Therapeutics, exercised stock options to acquire 30,000 shares of common stock at $1.39 per share on April 23, 2024.
Summary
- On April 23, 2024, Earl M Collier Jr., a director of Capricor Therapeutics, exercised stock options.
- This transaction involved the acquisition of 30,000 shares of common stock at a price of $1.39 per share.
- Following the transaction, Collier directly owns 56,856 shares of common stock.
- Collier also owns 53,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a stock option exercise. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, or those holding 10% or more of a company's shares) trade in their company's stock. These filings provide transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| March 1, 2020 | Commencement of vesting schedule for stock options (1/48th per month). |
| February 12, 2030 | Expiration date of the stock options. |
| 04/23/2024 | Date of transaction: Director exercised stock options. |
| 04/25/2024 | Date of filing of the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.